Antisense Drug Against BCL-2 Effective in Animal Cancer Models

April 1, 1995

SAN DIEGO--Genta Incorporated's antisense oligonucleotide targeted against the BCL-2 gene has proved effective against drug-resistant cancers in certain animal models of follicular lymphoma and colon cancer, the company said.

SAN DIEGO--Genta Incorporated's antisense oligonucleotide targetedagainst the BCL-2 gene has proved effective against drug-resistantcancers in certain animal models of follicular lymphoma and coloncancer, the company said.

The BCL-2 gene is overexpressed in many tumors, preventing normalapoptosis and inducing drug resistance. A phase I/II trial indrug-resistant follicular lymphoma is scheduled to begin at TheRoyal Marsden Hospital, London, by mid-year.